Pharmacologic therapies across the continuum of left ventricular dysfunction

The American Journal of Cardiology
William T AbrahamClyde W Yancy

Abstract

Neurohormonal activation and increased sympathetic stimulation are among the factors that have been linked to the development and progression of left ventricular dysfunction (LVD) and heart failure (HF) in post-myocardial infarction (MI) patients. Various available pharmacologic therapies can target these factors and improve many aspects of the disease, depending on the degree of LVD. The American College of Cardiology/American Heart Association (ACC/AHA) guidelines recommend angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, and aldosterone antagonists because of their proven favorable effects on symptoms, left ventricular function, cardiac remodeling, hospitalization rates, and survival. However, they are not being used in over two thirds of patients with post-MI LVD. This review illustrates the impact of these therapies on post-MI LVD patients using evidence from multiple clinical trials. In addition, current and emerging treatments for acute decompensated HF will be outlined.

References

Aug 1, 1991·The New England Journal of Medicine·UNKNOWN SOLVD InvestigatorsJay N Cohn
Sep 27, 1984·The New England Journal of Medicine·J N CohnT Rector
Apr 2, 1981·The New England Journal of Medicine·UNKNOWN Norwegian Multicenter Study Group
Nov 1, 1993·American Heart Journal·A SigurdssonK Swedberg
Mar 1, 1993·British Heart Journal·S G RayS M Cobbe
Aug 26, 1998·The New England Journal of Medicine·S S GottliebR A Vogel
Jan 5, 2002·The New England Journal of Medicine·J N CohnUNKNOWN Valsartan Heart Failure Trial Investigators
Oct 18, 2002·American Journal of Physiology. Heart and Circulatory Physiology·Ricardo RochaJohn A Delyani
Dec 31, 2002·Journal of Molecular and Cellular Cardiology·Claude Delcayre, Bernard Swynghedauw
Apr 2, 2003·The New England Journal of Medicine·Bertram PittUNKNOWN Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators
Jun 18, 2003·Nihon rinsho. Japanese journal of clinical medicine·Hitoshi Takano, Morimasa Takayama
Jul 10, 2003·American Heart Journal·Craig R LeeKirkwood F Adams
Sep 19, 2003·Lancet·Marc A PfefferUNKNOWN CHARM Investigators and Committees
Nov 12, 2003·The New England Journal of Medicine·Marc A PfefferUNKNOWN Valsartan in Acute Myocardial Infarction Trial Investigators
Feb 27, 2004·European Heart Journal·Michael M Givertz, Eugene Braunwald
Feb 27, 2004·European Heart Journal·Roberto LatiniUNKNOWN Val-HeFT Investigators
Nov 9, 2004·The New England Journal of Medicine·Eugene BraunwaldUNKNOWN PEACE Trial Investigators
Mar 23, 2005·Circulation·Jonathan D Sackner-BernsteinKeith D Aaronson
Nov 8, 2005·Lancet·Z M ChenUNKNOWN COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group
Jan 6, 2006·Current Medical Research and Opinion·Randall E Williams
Feb 28, 2006·Journal of Cardiac Failure·UNKNOWN Heart Failure Society Of America

❮ Previous
Next ❯

Citations

Dec 2, 2009·Current Heart Failure Reports·Farouk Mookadam, Sherif E Moustafa
Sep 28, 2012·Journal of Cardiovascular Translational Research·Melissa L Martin, Burns C Blaxall
Nov 15, 2011·American Journal of Physiology. Heart and Circulatory Physiology·Guangmao ChengGeorge Cooper
Feb 10, 2009·American Journal of Physiology. Heart and Circulatory Physiology·Jian-Bing ShenBruce T Liang
Mar 17, 2010·International Journal of Cardiology·Claudia StöllbergerJosef Finsterer
Dec 2, 2009·The American Journal of Geriatric Pharmacotherapy·Judy W M Cheng, Monica Nayar
Feb 8, 2011·The American Journal of Cardiology·Gaetano SantulliGuido Iaccarino
Jul 15, 2009·Journal of Cardiovascular Pharmacology·Junko Kurokawa, Hugues Abriel
Mar 25, 2019·European Heart Journal·Amie J MoyesAdrian J Hobbs
Jul 18, 2018·Proceedings of the National Academy of Sciences of the United States of America·Reshma S BaligaAdrian J Hobbs

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Cardiac Remodeling

Cardiac remodeling in response to a myocardial infarction is characterized by progressive ventricular dilatation, cardiac hypertrophy, fibrosis, and deterioration of cardiac performance. Discover the latest research on Cardiac Remodeling here.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Brain Ischemia

Brain ischemia is a condition in which there is insufficient blood flow to the brain to meet metabolic demand. Discover the latest research on brain ischemia here.